Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 225

Sort by

Sort Order Select

Journal Articles

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Kitsada Wudhikarn, Jessica R. Flynn, Isabelle Rivière, Mithat Gönen, Xiuyan Wang, Brigitte Senechal, Kevin J. Curran, Mikhail Roshal, Peter G. Maslak, Mark B. Geyer, Elizabeth F. Halton, Claudia Diamonte, Marco L. Davila, Michel Sadelain, Renier J. Brentjens, Jae H. Park

Blood (2021) 138 (7): 531–543.

https://doi.org/10.1182/blood.2020009515

Published: 2021

Includes: Supplemental data

Journal Articles

DARTs point the way forward in AML

Saar Gill

Blood (2021) 137 (6): 720–721.

https://doi.org/10.1182/blood.2020009020

Published: 2021

Journal Articles

Blinatumomab for infant acute lymphoblastic leukemia

Katherine Clesham, Vasudha Rao, Jack Bartram, Philip Ancliff, Sara Ghorashian, David O’Connor, Vesna Pavasovic, Anupama Rao, Sujith Samarasinghe, Michelle Cummins, Andrea Malone, Katharine Patrick, Denise Bonney, Beki James, Brenda Gibson, Ajay Vora

Blood (2020) 135 (17): 1501–1504.

https://doi.org/10.1182/blood.2019004008

Published: 2020

Journal Articles

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Ibrahim Aldoss, Stephen J. Forman

Blood (2020) 135 (11): 804–813.

https://doi.org/10.1182/blood.2019002132

Published: 2020

Journal Articles

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331

Patrick A. Brown, MD, Lingyun Ji, PhD, Xinxin Xu, MS, Meenakshi Devidas, PhD, Laura Hogan, MD, Michael J. Borowitz, MD PhD, Elizabeth A. Raetz, MD, Gerhard Zugmaier, Elad Sharon, MD MPH, Lia Gore, MD, James A. Whitlock, MD, Michael A. Pulsipher, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_2): LBA-1.

https://doi.org/10.1182/blood-2019-132435

Published: 2019

Journal Articles

Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Xian Zhang, MD, Junfang Yang, MD, Yanze Shi, Dan Song, Jingjing Li, Xin-an Lu, PhD, Fei Wu, Jianqiang Li, Ph. D., Dandan Chen, Xiangqun Li, Zhongwei Xu, Shuqiang Liu, Ziyu Li, Kui YIng, Wenya Wang, Peihua Lu

Blood (2019) 134 (Supplement_1): 224.

https://doi.org/10.1182/blood-2019-125503

Published: 2019

Journal Articles

SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia

Anjali S. Advani, MD, Anna Moseley, M.S., Michaela Liedtke, MD, Margaret R O'Donnell, MD, Ibrahim Aldoss, MD, Martha P. Mims, MD PhD, Kristen Marie O'Dwyer, MD, Megan Othus, PhD, Harry P. Erba, MD PhD

Blood (2019) 134 (Supplement_1): 227.

https://doi.org/10.1182/blood-2019-125340

Published: 2019

Journal Articles

Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2019) 134 (Supplement_1): 283.

https://doi.org/10.1182/blood-2019-125146

Published: 2019

Journal Articles

AUTO1, a Novel Fast Off CD19CAR Delivers Durable Remissions and Prolonged CAR T Cell Persistence with Low CRS or Neurotoxicity in Adult ALL

Blood (2019) 134 (Supplement_1): 226.

https://doi.org/10.1182/blood-2019-131086

Published: 2019

Journal Articles

Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era

Sanghee Hong, MD, Lisa Rybicki, MS, Donna Corrigan, Betty K. Hamilton, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Robert M. Dean, MD, Brian T. Hill, MD, Brad Pohlman, MD, Deepa Jagadeesh, MDMPH, Faiz Anwer, MD, Navneet S. Majhail, MD MS

Blood (2019) 134 (Supplement_1): 4567.

https://doi.org/10.1182/blood-2019-124533

Published: 2019

Journal Articles

Real World Chart Review of Blinatumomab to Treat Patients with High Disease Burden of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Amber C. King, PharmD, BCOP, Rachel Bolanos, PhD MPH, Kelly Velasco, PharmD, Huakang Tu, PhD, Faraz Zaman, MD, Mark B. Geyer, MD, Jae H. Park, MD

Blood (2019) 134 (Supplement_1): 5079.

https://doi.org/10.1182/blood-2019-122745

Published: 2019

Journal Articles

Bispecific T-Cell Engager (BiTE) Antibody Based Immunotherapy for Treatment of Relapsed Refractory Multiple Myeloma (RRMM): A Systematic Review of Preclinical and Clinical Trials

Zunairah Shah, MBBS, Mustafa Nadeem Malik, MD, Syeda Sabeeka Batool, MBBS, MD, Sravanthi Kotapati, MBBS, Aisha Akhtar, MBBS, Owais ur Rehman, MBBS, Marium Ghani, MBBS, Maryam Sadiq, MBBS, Arshia Akbar, MD, Aqsa Ashraf, MBBS, Arafat Ali Ali Farooqui, MD, Muhammad Abdullah Yousaf, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Hafiz Muhammad Fazeel, MBBS, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5567.

https://doi.org/10.1182/blood-2019-129652

Published: 2019

Journal Articles

Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

Michela Ansuinelli, MD, Antonella Vitale, MD, Giovanna Pecoraro, MD, Saveria Capria, MD, Silvia Maria Trisolini, MD, Clara Minotti, MD, Claudio Cartoni, MD, Anna Maria Testi, MD, Maria Luisa Moleti, MD, Anna Paola Iori, MD, Walter Barberi, MD PhD, Irene Della Starza, PhD, Loredana Elia, Bs, Francesca Mancini, Maria Stefania De Propris, Anna Guarini, PhD, Sabina Chiaretti, MD PhD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 5121.

https://doi.org/10.1182/blood-2019-128156

Published: 2019

Journal Articles

Successful Treatment of Refractory Acute Lymphoblastic Leukemia with Tisagenlecleucel in the Setting of Life-Threatening Infection

Keith J August, MDMS, Terrie Flatt, DO,MA, Erin Marie Hall, MD, Doug Myers, MD

Blood (2019) 134 (Supplement_1): 5125.

https://doi.org/10.1182/blood-2019-130880

Published: 2019

Journal Articles

Blinatumomab and Venetoclax for Minimal Residual Disease Relapse in Acute Lymphoblastic Leukemia

Gregorio Campos-Cabrera, MD, Noe-Benjamin Vega-Tapia, MD, Virgina Campos-Cabrera, QFB EBC, Salvador Campos-Cabrera, MD, Jose-Luis Campos-Villagomez, MD, Esther Mendez-Garcia, MD

Blood (2019) 134 (Supplement_1): 5128.

https://doi.org/10.1182/blood-2019-127296

Published: 2019

Journal Articles

Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL

Yukio Kobayashi, Iekuni Oh, MD PhD, Toshihiro Miyamoto, MD PhD, Won-Sik Lee, Hiroatsu Iida, MD PhD, Hironobu Minami, MD PhD, Yoshinobu Maeda, MD PhD, Jun Ho Jang, Sung-Soo Yoon, MD PhD, Su-Peng Yeh, MD, Qui Tran, Joan Morris, Janet L. Franklin, Ka-Wing Chong, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 5069.

https://doi.org/10.1182/blood-2019-124582

Published: 2019

Journal Articles

Is It Time to Take MRD More Seriously? Relationship between MRD, Functional Cure and Life Expectancy Among Patients with Ph- B Cell Precursor ALL (BCP-ALL)

Qiujun Shao, Simran Tiwana, Nicholas Despiegel, Franziska Dirnberger

Blood (2019) 134 (Supplement_1): 5814.

https://doi.org/10.1182/blood-2019-126309

Published: 2019

Journal Articles

Effective Targeting of PRAME-Positive Tumors with Bispecific T Cell-Engaging Receptor (TCER ® ) Molecules

Sebastian Bunk, PhD, Martin Hofmann, PhD, Felix Unverdorben, PhD, Meike Hutt, PhD, Gabriele Pszolla, PhD, Frank Schwöbel, PhD, Claudia Wagner, PhD, Sara Yousef, PhD, Heiko Schuster, PhD, Sarah Missel, PhD, Oliver Schoor, PhD, Toni Weinschenk, PhD, Harpreet Singh-Jasuja, PhD, Dominik Maurer, PhD, Carsten Reinhardt, MD

Blood (2019) 134 (Supplement_1): 3368.

https://doi.org/10.1182/blood-2019-129958

Published: 2019

Journal Articles

Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity

Meixiao Long, MD, Erich Williams, Clara Berard, Carolyn Cheney, BS, Eileen Hu, BS, Seema A. Bhat, MD, Kerry A. Rogers, MD, Jennifer Woyach, MD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1049.

https://doi.org/10.1182/blood-2019-125417

Published: 2019

Journal Articles

Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO)

Franco Locatelli, MD, Gerhard Zugmaier, Peter Bader, MD, Sima Jeha, MD, Paul-Gerhardt Schlegel, Jean-Pierre Bourquin, MD PhD, Rupert Handgretinger, MD, Benoit Brethon, MD, Claudia Rossig, Christiane Chen-Santel

Blood (2019) 134 (Supplement_1): 1294.

https://doi.org/10.1182/blood-2019-121615

Published: 2019

NARROW

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

DARTs point the way forward in AML

Blinatumomab for infant acute lymphoblastic leukemia

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)

SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia

Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

AUTO1, a Novel Fast Off CD19CAR Delivers Durable Remissions and Prolonged CAR T Cell Persistence with Low CRS or Neurotoxicity in Adult ALL

Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era

Real World Chart Review of Blinatumomab to Treat Patients with High Disease Burden of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Bispecific T-Cell Engager (BiTE) Antibody Based Immunotherapy for Treatment of Relapsed Refractory Multiple Myeloma (RRMM): A Systematic Review of Preclinical and Clinical Trials

Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

Successful Treatment of Refractory Acute Lymphoblastic Leukemia with Tisagenlecleucel in the Setting of Life-Threatening Infection

Blinatumomab and Venetoclax for Minimal Residual Disease Relapse in Acute Lymphoblastic Leukemia

Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL

Is It Time to Take MRD More Seriously? Relationship between MRD, Functional Cure and Life Expectancy Among Patients with Ph- B Cell Precursor ALL (BCP-ALL)

Effective Targeting of PRAME-Positive Tumors with Bispecific T Cell-Engaging Receptor (TCER ® ) Molecules

Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity

Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only